- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Novo Nordisk to cease distribution of Tresiba in Germany
2 July 2015 • Author: Victoria White
Novo Nordisk has decided to cease distribution of its once-daily basal insulin Tresiba (insulin degludec) in Germany.
The decision follows a negative outcome of price negotiations with the GKV-Spitzenverband, the German national association of statutory health insurance funds. In order to ensure a safe switch to another insulin treatment for the 40,000 people with diabetes currently using Tresiba, Novo Nordisk will continue supplying the product until the end of September 2015.
Decision to cease distribution of Tresiba in Germany has no implications for other countries
“We are very sad that it has not been possible to reach a price agreement with the insurance fund,” said Jakob Riis, executive vice president in Novo Nordisk. “Tresiba offers important benefits for many people with diabetes as recognised by the European health authorities (EMA), among others. The GKV-Spitzenverband decided nevertheless to set the price at the level of ordinary human insulin, a product which was launched in the 1980s. If we were to accept this price, we would undermine our ability to research and develop medical innovations for people with diabetes. That would not be in the best interest of the millions of people with diabetes for whom current treatments are insufficient to control their disease. We deeply regret the uncertainty and inconvenience this situation creates for the affected patients and physicians in Germany, and will do our utmost to support them in the process of switching patients to another insulin treatment.”
Tresiba has been launched in 30 countries. The decision to cease distribution of Tresiba in Germany has no implications for the other countries where the product is available.
Tresiba (insulin degludec) is a once-daily basal insulin that provides an ultra-long duration of action beyond 42 hours.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics